ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

ClinicalTrials.gov ID: NCT05367440

Public ClinicalTrials.gov record NCT05367440. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Study identification

NCT ID
NCT05367440
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
174 participants

Conditions and interventions

Interventions

  • AZD5305 Drug
  • Abiraterone Acetate Drug
  • Apalutamide Drug
  • Darolutamide Drug
  • Enzalutamide Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 1, 2022
Primary completion
Apr 10, 2031
Completion
Apr 10, 2031
Last update posted
Dec 7, 2025

2022 – 2031

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Research Site Detroit Michigan 48201
Research Site Detroit Michigan 48202
Research Site Syracuse New York 13210
Research Site Myrtle Beach South Carolina 29572
Research Site Houston Texas 77030
Research Site Houston Texas 77094

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05367440, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 7, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05367440 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →